AGTC Genomics and Zell-V Wellness Explore Solutions to the Diagnostic Gap in Wellness and Longevity Medicine
Exploratory discussion highlights evidence-based testing, clinical validation and expert interpretation as foundations for personalised healthy ageing
AGTC Genomics and Zell-V Wellness, also known as V-Wellness, held a fruitful discussion exploring how advanced diagnostics could strengthen personalised wellness and longevity care. The exchange centred on an important challenge: translating growing interest in healthy ageing into reliable assessments, informed clinical decisions and meaningful follow-up.
As more people seek to preserve their energy, mobility and quality of life as they age, healthcare providers face a practical question: how can they identify what each individual needs and determine whether a care plan is making a meaningful difference? Addressing this diagnostic gap requires reliable measurements supported by appropriate evidence and interpreted within the individual’s medical context.
V-Wellness is an integrated healthcare centre whose medical team brings more than 30 years of collective experience. Its approach draws on integrative and regenerative medicine, with an emphasis on personalised care and understanding the individual’s health, lifestyle and goals. Its four-step framework encompasses assessment, detoxification, boosting and rejuvenation.
The discussion provided an opportunity to explore how AGTC Genomics’ diagnostic capabilities could complement V-Wellness’s emphasis on individual assessment and ongoing care. A stronger evidence base for assessment and monitoring could help practitioners set clearer priorities, explain findings to clients and review progress against appropriate health outcomes.
Connecting molecular insights with everyday health
Longevity medicine aims to support more years of good health, independence and function. Genomic testing can provide information about inherited predispositions, while epigenetic analysis examines chemical marks associated with how genes are regulated. Certain DNA methylation patterns can be used to estimate aspects of biological ageing, offering a different perspective from the number of birthdays a person has had.
These approaches create opportunities to investigate why people of the same chronological age may show different ageing patterns. When supported by evidence for the intended use, molecular insights may complement medical history, physical examination, routine blood tests and functional assessments to inform more individualised care.
Evidence and clinical validation must guide adoption
For AGTC Genomics, responsible adoption begins with asking whether a test measures its target reliably, whether the result is meaningfully related to the health outcome being assessed, and whether using that result improves care. These are distinct requirements: a technically accurate measurement alone does not establish that a test can guide a particular treatment.
Biological age and epigenetic scores also require careful interpretation. Recent research demonstrates that different epigenetic clocks respond differently to interventions, with results influenced by the study population and duration. A change in a score should therefore be considered alongside established clinical and functional outcomes; it does not, by itself, demonstrate longer life or successful regeneration of an organ.
Expert interpretation turns results into appropriate care
The value of testing depends on what happens after the report is issued. Qualified healthcare professionals should interpret results alongside symptoms, family history, medication use, lifestyle and other investigations. Clear explanations should distinguish established findings from emerging indicators and connect actionable results to an appropriate care or referral plan.
The exploration with V-Wellness represents an opportunity to connect personalised wellness services with rigorous diagnostic science. AGTC Genomics welcomes continued dialogue on how evidence-based assessment, clinically validated testing and expert interpretation can support more informed choices and better healthy-ageing care.
About AGTC Genomics
AGTC Genomics is a Malaysian precision medicine and advanced molecular diagnostics company providing genomic testing and research services across oncology, inherited diseases, infectious diseases and precision health. Its advanced genomics laboratory in Bukit Jalil, Kuala Lumpur, holds ISO 15189, ISO/IEC 17025 and College of American Pathologists (CAP) accreditations. Learn more at https://www.agtcgenomics.com/.
AGTC Genomics and Zell-V Wellness representatives during a knowledge-sharing session exploring the role of advanced diagnostics in personalised wellness and longevity medicine.
An exchange between the AGTC Genomics and Zell-V Wellness teams on strengthening assessment and interpretation to support more informed approaches to healthy ageing.
Comments